Status:
ACTIVE_NOT_RECRUITING
Understanding the Immune System's Role in Tree Nut and Peanut Allergies: Key Biomarkers for Diagnosis and Treatment Monitoring and Treatment Targets
Lead Sponsor:
Luxembourg Institute of Health
Collaborating Sponsors:
Centre Hospitalier du Luxembourg
Conditions:
Food Allergy
Food Allergy in Children
Eligibility:
All Genders
2-70 years
Brief Summary
Peanut and tree nuts belong to the main elicitors of pediatric food allergy and are the main cause of near fatal reactions in children requiring emergency management. Oral immunotherapy has emerged as...
Detailed Description
Background: The prevalence of peanut together with tree nut allergies have increase over the years and accounts for most of the life-threatening reactions even to minute doses of the allergen. Consequ...
Eligibility Criteria
Inclusion
- For Peanut and Tree nut Allergic participants
- Inclusion criteria:
- More than 2 years
- Male or Female
- Allergic to peanut (assessed by anamnesis, skin reactivity testing, sera testing for specific IgE)
- Sign an Informed Consent
- Exclusion criteria:
- Pregnancy
- Less than 2 years of age
- Co-existing chronic medical condition such as cardiovascular disorders
- Peanut or tree nut-allergic patients/families who are unwilling to undergo oral food challenges
- The eligible participants will be assigned to the oral immunotherapy (OIT) group but if they are not eligible for OIT based on either on the reasons mentioned below, they will be assigned to the avoidance group.
- Reasons for ineligibility of OIT :
- risk of poor compliance with immunotherapy
- lack of understanding of the OIT protocol
- uncontrolled asthma
- incompatibility with lifestyle (regular intense physical activities, multiple vacations)
- unwilling to undergo OIT
- long-term or frequent use of non-steroidal anti-inflammatory drugs
- multiple nut allergy with no direct clinical benefit of OIT to one nut
- co-existing comorbidities such as active systemic autoimmune diseases, active malignancy, eosinophilic esophagitis.
- For Healthy Controls
- Adults
- Male or Female
- Sign an Informed Consent
- Tolerates any type of nut
- No known food allergy
Exclusion
- Pregnancy
- Co-existing chronic medical condition such as cardiovascular disorders
Key Trial Info
Start Date :
October 2 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT06554691
Start Date
October 2 2023
End Date
December 1 2026
Last Update
December 2 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier de Luxembourg
Luxembourg, Luxembourg, 1210
2
Clinical and Epidemiological Investigation Center, Luxembourg Institute of Health
Luxembourg, Luxembourg, 1210